These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31150996)

  • 1. Quality of life after switching to generic levetiracetam - A prospective comparative study.
    Olsson P; Reimers A; Källén K
    Epilepsy Behav; 2019 Jul; 96():169-174. PubMed ID: 31150996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of generic substitution on levetiracetam serum concentration-A prospective study in an outpatient setting.
    Reimers A; Olsson P; Nilsson J; Hoff E; Reis M; Strandberg M; Lundgren A; Källén K
    Epilepsy Res; 2017 Aug; 134():54-61. PubMed ID: 28595756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting.
    Markoula S; Chatzistefanidis D; Gatzonis S; Siatouni A; Siarava E; Verentzioti A; Kyritsis AP; Patsalos PN
    Seizure; 2017 May; 48():1-6. PubMed ID: 28363098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brand name to generic substitution of levetiracetam in patients with epilepsy.
    Gha-Hyun L; Dae SJ
    Seizure; 2018 Aug; 60():127-131. PubMed ID: 29960217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brand-to-generic levetiracetam switching: a 4-year prospective observational real-life study.
    Trimboli M; Russo E; Mumoli L; Tripepi G; Fortunato F; Mastroianni G; Abate F; De Sarro G; Gambardella A; Labate A
    Eur J Neurol; 2018 Apr; 25(4):666-671. PubMed ID: 29322654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with generic levetiracetam in people with epilepsy.
    Chaluvadi S; Chiang S; Tran L; Goldsmith CE; Friedman DE
    Epilepsia; 2011 Apr; 52(4):810-5. PubMed ID: 21426334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
    Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
    Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.
    Contin M; Alberghini L; Candela C; Benini G; Riva R
    Epilepsy Res; 2016 May; 122():79-83. PubMed ID: 26987080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of switching from brand-name to generic levetiracetam in patients with epilepsy.
    Bosak M; Słowik A; Turaj W
    Drug Des Devel Ther; 2017; 11():2287-2291. PubMed ID: 28814836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.
    Vari MS; Pinto F; Mencaroni E; Giudizioso G; Minetti C; La Neve A; Francavilla T; Piccioli M; Striano S; del Gaudio L; Tovo P; Striano P; Verrotti A
    Clin Drug Investig; 2016 Jan; 36(1):87-91. PubMed ID: 26507620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch From Originator to Equivalent Drug in the Era of Generic Antiepileptic Drugs: Study of Keppra Versus Epitiram Clinical Equivalence.
    Fanella M; Morano A; Fattouch J; Albini M; Basili LM; Casciato S; Manfredi M; Giallonardo AT; Di Bonaventura C
    Clin Neuropharmacol; 2017; 40(6):239-242. PubMed ID: 28976412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B; Hemdal P; Privitera MD
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma.
    Cardona AF; Rojas L; Wills B; Bernal L; Ruiz-Patiño A; Arrieta O; Hakim EJ; Hakim F; Mejía JA; Useche N; Bermúdez S; Carranza H; Vargas C; Otero J; Mayor LC; Ortíz LD; Franco S; Ortíz C; Gil-Gil M; Balaña C; Zatarain-Barrón ZL
    J Neurooncol; 2018 Jan; 136(2):363-371. PubMed ID: 29177594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam.
    Yates SL; Fakhoury T; Liang W; Eckhardt K; Borghs S; D'Souza J
    Epilepsy Behav; 2015 Nov; 52(Pt A):165-8. PubMed ID: 26432008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the anticonvulsant activity of levetiracetam dose-dependent?
    Lamouret V; Kurth C; Intravooth T; Steinhoff BJ
    Seizure; 2020 Dec; 83():197-202. PubMed ID: 33197757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
    Andermann F; Duh MS; Gosselin A; Paradis PE
    Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between switching antiepileptic drug products and healthcare utilization: A systematic review.
    Kwan P; Palmini A
    Epilepsy Behav; 2017 Aug; 73():166-172. PubMed ID: 28641169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brand-to-generic oxcarbazepine switch - A prospective observational study.
    Bosak M; Słowik A; Dziedzic T
    Epilepsy Res; 2019 Mar; 151():75-77. PubMed ID: 30836239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of psychiatric and behavioral adverse effects of antiepileptic drugs monotherapy: Could they have a neuroendocrine correlation in persons with epilepsy?
    Sarangi SC; Kaur N; Tripathi M
    Epilepsy Behav; 2019 Nov; 100(Pt A):106439. PubMed ID: 31574428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies.
    Yamada M; Welty TE
    Ann Pharmacother; 2011 Nov; 45(11):1406-15. PubMed ID: 22028417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.